A 2-year investigation, consisting of a controlled, non-blind, 3-monthly chemotherapeutic intervention trial, based on transmission dynamics of Ascaris lumbricoides infection, was undertaken to prove or refute the role of A. lumbricoides as a contributor to childhood malnutrition. The study involved 1206 children aged 2-12 years in 21 villages in Myanmar [Burma] starting in August 1984. The intervention and non-intervention villages were comparable regarding almost all the important baseline variables, including prevalences of Ascaris infection (80.8 vs 83.0%) and of malnutrition of grade 2 and above for height-for-age (58.4 vs 55.8%) and for weight-for-age (48.2 vs 47.8%). The intensity of Ascaris infection was related to the degree of malnutrition. A significant increment of height gain was found, starting after the 6th month, and of weight gain after the 24th month, of the study among the treated 2-10 years old children when compared with the non-treated ones. By the end of 24 months, the height and weight gains per child were 0.65 cm and 0.93 kg respectively. Lesser increments in height-for-age and weight-for-age were also observed after successive treatments among the treated children with initially higher mean worm burdens. The findings are discussed in the context of causal relationship between ascariasis and malnutrition in children.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0035-9203(91)90242-qDOI Listing

Publication Analysis

Top Keywords

chemotherapeutic intervention
8
intervention trial
8
ascaris lumbricoides
8
lumbricoides infection
8
malnutrition children
8
ascaris infection
8
malnutrition
5
children
5
controlled chemotherapeutic
4
trial relationship
4

Similar Publications

Shared chemoresistance genes in ESCC and cervical Cancer: Insights from pharmacogenomics and Mendelian randomization.

Int Immunopharmacol

January 2025

Department of Pathology, Xiangya Hospital, Central South University, Changsha City, Hunan Province, China; Department of Pathology, School of Basic Medicine, Central South University, Changsha City, Hunan Province, China; Ultrapathology (Biomedical Electron Microscopy) Center, Department of Pathology, Xiang-ya Hospital, Central South University, Changsha City, Hunan Province, China; Key Laboratory of Hunan Province in Neurodegenerative Disorders, Xiangya Hospital, Central South University, Changsha City, Hunan Province, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha City, Hunan Province, China; FuRong Laboratory, Changsha City, Hunan Province, China. Electronic address:

Background: Neoadjuvant chemotherapy, particularly the use of platinum-based compounds and taxanes, is pivotal in the treatment of epithelial-derived tumors, such as cervical cancer and esophageal squamous cell carcinoma (ESCC); however, resistance remains a significant challenge. Utilizing Mendelian randomization (MR) with pharmacogenomics offers a novel approach to understanding the genetic underpinnings of drug responses, thereby aiding in personalized treatment.

Methods: Single-cell RNA sequencing (scRNA-seq) analysis revealed a shared cellular subpopulation of CD8 + T effector memory (CD8 + TEM) cells that are pivotal in mediating chemotherapy resistance in ESCC and cervical cancer.

View Article and Find Full Text PDF

The aim of the review was to systematically review real-world data on the effectiveness and safety of pembrolizumab in recurrent/metastatic/unresectable head and neck squamous cell cancer (HNSCC) patients. Two independent reviewers retrieved the studies separately and simultaneously. PubMed, Embase, Scopus, Web of Science, and Cochrane Central were searched for prospective and retrospective studies on recurrent/metastatic/unresectable HNSCC patients treated with either pembrolizumab monotherapy or pembrolizumab combination therapy published till November 2024.

View Article and Find Full Text PDF

Background: Pyroptosis is closely associated with chemotherapeutic drugs and immune response. Here, we investigated whether oxaliplatin, a key drug in FOLFOX-hepatic artery infusion chemotherapy (FOLFOX-HAIC), induces pyroptosis in hepatoma cells and enhances antitumor immunity after tumor cell death.

Methods: Hepatoma cells were treated with oxaliplatin.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on creating a new drug delivery system using dual-ligand-modified liposomes to target glioma, with the goal of overcoming the blood-brain barrier and improving drug effectiveness.
  • Researchers used a specific technique to prepare liposomes that co-load a photosensitizer (ICG) and a chemotherapeutic drug (MTO), and tested their properties and ability to penetrate the blood-brain barrier while targeting glioma cells.
  • Results showed that the modified liposomes were stable, capable of effectively penetrating the blood-brain barrier, concentrating in glioma cells, and exhibited strong anti-tumor effects, highlighting their potential in improving glioma treatment.
View Article and Find Full Text PDF

Chemotherapy is essential for treating tumors, including head and neck cancer (HNC). However, the toxic side effects of chemotherapeutic drugs limit their widespread use. Therefore, a targeted delivery system that can transport the drug to the pathological site while minimizing damage to healthy tissues is urgently needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!